Wedbush Reaffirms Buy Rating for Albireo Pharma (NASDAQ:ALBO)

Wedbush reiterated their buy rating on shares of Albireo Pharma (NASDAQ:ALBO) in a report published on Wednesday morning, AnalystRatings.com reports. They currently have a $69.00 price objective on the biopharmaceutical company’s stock.

ALBO has been the subject of several other research reports. HC Wainwright restated a buy rating and issued a $62.00 target price on shares of Albireo Pharma in a report on Sunday, August 11th. BidaskClub cut shares of Albireo Pharma from a sell rating to a strong sell rating in a report on Tuesday, October 1st. William Blair restated a buy rating on shares of Albireo Pharma in a report on Monday, July 15th. Finally, Zacks Investment Research cut shares of Albireo Pharma from a hold rating to a sell rating in a report on Wednesday, October 9th. Two investment analysts have rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the stock. Albireo Pharma presently has a consensus rating of Buy and an average price target of $49.00.

Shares of Albireo Pharma stock traded down $0.07 on Wednesday, reaching $18.94. The company had a trading volume of 28,200 shares, compared to its average volume of 51,338. The firm’s 50 day moving average price is $19.22 and its two-hundred day moving average price is $27.04. Albireo Pharma has a 52-week low of $16.13 and a 52-week high of $38.69. The firm has a market cap of $257.26 million, a PE ratio of -4.81 and a beta of 1.47.

Albireo Pharma (NASDAQ:ALBO) last issued its earnings results on Wednesday, November 6th. The biopharmaceutical company reported ($1.73) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.55) by ($0.18). Albireo Pharma had a negative net margin of 2,403.88% and a negative return on equity of 51.74%. The company had revenue of $1.39 million during the quarter, compared to analyst estimates of $1.38 million. Analysts anticipate that Albireo Pharma will post -5.91 EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. Aperio Group LLC acquired a new stake in Albireo Pharma during the 2nd quarter worth $42,000. Meeder Asset Management Inc. boosted its stake in Albireo Pharma by 796.5% during the 2nd quarter. Meeder Asset Management Inc. now owns 2,026 shares of the biopharmaceutical company’s stock worth $65,000 after purchasing an additional 1,800 shares during the period. JPMorgan Chase & Co. boosted its stake in Albireo Pharma by 27.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 2,836 shares of the biopharmaceutical company’s stock worth $90,000 after purchasing an additional 614 shares during the period. D. E. Shaw & Co. Inc. acquired a new stake in Albireo Pharma during the 2nd quarter worth $233,000. Finally, Hartwell J M Limited Partnership boosted its stake in Albireo Pharma by 8.8% during the 2nd quarter. Hartwell J M Limited Partnership now owns 15,500 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 1,250 shares during the period. Hedge funds and other institutional investors own 73.21% of the company’s stock.

About Albireo Pharma

Albireo Pharma, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases.

Recommended Story: Calculate Your Return on Investment (ROI)

Analyst Recommendations for Albireo Pharma (NASDAQ:ALBO)

Receive News & Ratings for Albireo Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Albireo Pharma and related companies with MarketBeat.com's FREE daily email newsletter.